CFO John Dahldorf resigns; FULCRUM-VT trial enrollment exceeds 40%

Adagio Medical Holdings, Inc.

CFO John Dahldorf resigns effective March 21, 2025, no dispute over accounting; transitional CFO to be named.
FULCRUM-VT pivotal study (vCLAS catheter) enrollment over 40%, on track for full enrollment H2 2025.
Company to present ULTC data at EHRA 2025 (March 30-April 1) on scar-related VT and PVC ablation.
Streamlining focus on ventricular tachycardia solutions; CEO notes sufficient financial resources to achieve goals.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Dahldorf

Chief Financial Officer

ADGM · Adagio Medical Holdings, Inc.

Effective: 2025-03-21
Filed: March 17, 2025, 7:59 PM ET

On March 11, 2025, John Dahldorf, the Chief Financial Officer of Adagio Medical Holdings, Inc. (the “Company”) announced his decision to resign as Chief Financial Officer, effective March 21, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Dahldorf resigned as Chief Financial Officer at Adagio Medical Holdings, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 11, 2025, John Dahldorf, the Chief Financial Officer of Adagio Medical Holdings, Inc. (the “Company”) announced his decision to resign as Chief Financial Officer, effective March 21, 2025.

View on SEC.gov

Adagio Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-024408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.